Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether a 6-week treatment with 4 g Omacor/day improves the baseline and postprandial endothelial function (after a high-fat meal) in patients with type 2 diabetes mellitus.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ruhr University of Bochum
• Collaborators: Heart and Diabetes Center North-Rhine Westfalia; Solvay Pharmaceuticals

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus

Exclusion Criteria:

• History of myocardial infarction, stroke

• Severe diabetes complications

• Severe hypo- or hypertension

• Chronic alcohol abuse

• Renal failure